This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2020
  • /
  • 05
  • /
  • CHMP recommends Insulin aspart Sanofi, a biosimila...
Drug News

CHMP recommends Insulin aspart Sanofi, a biosimilar product, intended for the treatment of diabetes mellitus.- Sanofi

Read time: 1 mins
Published:3rd May 2020
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Insulin aspart Sanofi, intended for the treatment of diabetes mellitus. The applicant for this medicinal product is sanofi-aventis groupe. Insulin aspart Sanofi will be available as a solution for injection (100 units/ml). The active substance of Insulin aspart Sanofi is insulin aspart, a fast-acting insulin analogue (ATC code: A10AB04) which is absorbed more rapidly by the body and can therefore act faster than human insulin. The replacement insulin acts in the same way as naturally produced insulin; it works by facilitating uptake of glucose into skeletal muscle and fat tissue, and by inhibiting glucose output from the liver. Insulin aspart Sanofi is a biosimilar medicinal product. It is highly similar to the reference product NovoRapid (insulin aspart), which was authorised in the EU on 7 September 1999. Data show that Insulin aspart Sanofi has comparable quality, safety and efficacy to NovoRapid (insulin aspart).
Condition: Diabetes Type 2
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.